271 related articles for article (PubMed ID: 22809706)
1. Long-term relationship between methylphenidate and tobacco consumption and nicotine craving in adults with ADHD in a prospective cohort study.
Bron TI; Bijlenga D; Kasander MV; Spuijbroek AT; Beekman AT; Kooij JJ
Eur Neuropsychopharmacol; 2013 Jun; 23(6):542-54. PubMed ID: 22809706
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
[TBL] [Abstract][Full Text] [Related]
3. Do stimulants reduce the risk for cigarette smoking in youth with attention-deficit hyperactivity disorder? A prospective, long-term, open-label study of extended-release methylphenidate.
Hammerness P; Joshi G; Doyle R; Georgiopoulos A; Geller D; Spencer T; Petty CR; Faraone SV; Biederman J
J Pediatr; 2013 Jan; 162(1):22-7.e2. PubMed ID: 22878114
[TBL] [Abstract][Full Text] [Related]
4. Long-acting methylphenidate reduces collision rates of young adult drivers with attention-deficit/hyperactivity disorder.
Cox DJ; Davis M; Mikami AY; Singh H; Merkel RL; Burket R
J Clin Psychopharmacol; 2012 Apr; 32(2):225-30. PubMed ID: 22367664
[TBL] [Abstract][Full Text] [Related]
5. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study.
Konstenius M; Jayaram-Lindström N; Beck O; Franck J
Drug Alcohol Depend; 2010 Apr; 108(1-2):130-3. PubMed ID: 20015599
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
Golubchik P; Sever J; Weizman A
Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
[TBL] [Abstract][Full Text] [Related]
7. Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.
Cho SC; Kim BN; Cummins TD; Kim JW; Bellgrove MA
J Psychopharmacol; 2012 Mar; 26(3):380-9. PubMed ID: 21628343
[TBL] [Abstract][Full Text] [Related]
8. The beneficial effect of methylphenidate in ADHD with comorbid separation anxiety.
Golubchik P; Golubchik L; Sever JM; Weizman A
Int Clin Psychopharmacol; 2014 Sep; 29(5):274-8. PubMed ID: 24743562
[TBL] [Abstract][Full Text] [Related]
9. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
[TBL] [Abstract][Full Text] [Related]
10. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate.
Buitelaar JK; Sobanski E; Stieglitz RD; Dejonckheere J; Waechter S; Schäuble B
J Clin Psychiatry; 2012 Aug; 73(8):1097-102. PubMed ID: 22780962
[TBL] [Abstract][Full Text] [Related]
11. Effect of osmotic-release oral system methylphenidate on learning skills in adolescents with attention-deficit/hyperactivity disorder: an open-label study.
Na KS; Lee SI; Hong SD; Kim JH; Shim SH; Choi J; Yang J; Lee MS; Joung YS; Kim EJ; Park JH
Int Clin Psychopharmacol; 2013 Jul; 28(4):184-92. PubMed ID: 23587983
[TBL] [Abstract][Full Text] [Related]
12. Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: a pilot randomized placebo-controlled trial.
Hurt RD; Ebbert JO; Croghan IT; Schroeder DR; Sood A; Hays JT
J Negat Results Biomed; 2011 Jan; 10():1. PubMed ID: 21276244
[TBL] [Abstract][Full Text] [Related]
13. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
Fallu A; Richard C; Prinzo R; Binder C
Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
[TBL] [Abstract][Full Text] [Related]
14. Effect of methylphenidate on the quality of life in children with epilepsy and attention deficit hyperactivity disorder: and open-label study using an osmotic-controlled release oral delivery system.
Yoo HK; Park S; Wang HR; Lee JS; Kim K; Paik KW; Yum MS; Ko TS
Epileptic Disord; 2009 Dec; 11(4):301-8. PubMed ID: 20007067
[TBL] [Abstract][Full Text] [Related]
15. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
[TBL] [Abstract][Full Text] [Related]
16. When does it end? Attention-deficit/hyperactivity disorder in the middle aged and older populations.
Manor I; Rozen S; Zemishlani Z; Weizman A; Zalsman G
Clin Neuropharmacol; 2011; 34(4):148-54. PubMed ID: 21738027
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study.
Adler LA; Orman C; Starr HL; Silber S; Palumbo J; Cooper K; Berwaerts J; Harrison DD
J Clin Psychopharmacol; 2011 Feb; 31(1):108-14. PubMed ID: 21192153
[TBL] [Abstract][Full Text] [Related]
18. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants.
Lambert NM; Hartsough CS
J Learn Disabil; 1998; 31(6):533-44. PubMed ID: 9813951
[TBL] [Abstract][Full Text] [Related]
20. Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study.
Jafarinia M; Mohammadi MR; Modabbernia A; Ashrafi M; Khajavi D; Tabrizi M; Yadegari N; Akhondzadeh S
Hum Psychopharmacol; 2012 Jul; 27(4):411-8. PubMed ID: 22806822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
